bluebird bio, Inc.

MUN:BLE0 Stock Report

Market Cap: €71.6m

bluebird bio Management

Management criteria checks 2/4

bluebird bio's CEO is Andrew Obenshain, appointed in Nov 2021, has a tenure of 3.08 years. total yearly compensation is $3.05M, comprised of 22.4% salary and 77.6% bonuses, including company stock and options. directly owns 0.049% of the company’s shares, worth €35.18K. The average tenure of the management team and the board of directors is 2.6 years and 13.8 years respectively.

Key information

Andrew Obenshain

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage22.4%
CEO tenure3.1yrs
CEO ownership0.05%
Management average tenure2.6yrs
Board average tenure13.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andrew Obenshain's remuneration changed compared to bluebird bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$293m

Jun 30 2024n/an/a

-US$319m

Mar 31 2024n/an/a

-US$301m

Dec 31 2023US$3mUS$682k

-US$212m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$2mUS$643k

-US$230m

Sep 30 2022n/an/a

-US$431m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$563m

Dec 31 2021US$9mUS$486k

-US$563m

Compensation vs Market: Andrew's total compensation ($USD3.05M) is above average for companies of similar size in the German market ($USD468.04K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Obenshain (50 yo)

3.1yrs

Tenure

US$3,049,181

Compensation

Mr. Andrew Obenshain has been the President, Chief Executive Officer and Director of bluebird bio, Inc. since November 2021. He served as President of Severe Genetic Diseases since October 2020 until Novem...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Obenshain
President3.1yrsUS$3.05m0.049%
€ 35.2k
Thomas Klima
Chief Commercial Officer & COO2.3yrsUS$1.33m0.087%
€ 62.6k
Richard Colvin
Chief Medical Officer3.8yrsUS$1.34m0.025%
€ 17.7k
Oliver Sterling
CFO & Principal Accounting Officerless than a yearno datano data
Joseph Vittiglio
Chief Legal & Business Officer and Secretary1.9yrsno data0.0037%
€ 2.7k
Jess Rowlands
Head of Corporate Communications2yrsno datano data
Andrea Walton
Chief People Officer2.9yrsno datano data
Kasra Kasraian
Senior VP of Qualityno datano datano data
Scott Shoemaker
Senior VP of Technical Operations3.9yrsno datano data
Courtney O'Leary
Investor Relations Officerno datano datano data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Management: BLE0's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Obenshain
President3.1yrsUS$3.05m0.049%
€ 35.2k
Philip Reilly
Member of Scientific Advisory Board13.8yrsno datano data
Philippe Leboulch
Co-Chair of Scientific Advisory Boardno datano datano data
Stephen Goff
Member of Scientific Advisory Board13.8yrsno datano data
Mark Vachon
Independent Chairman10.4yrsUS$200.91k0.013%
€ 9.2k
Mitchell Finer
Member of Scientific Advisory Board9.4yrsUS$1.57mno data
Malcolm Brenner
Member of Scientific Advisory Board13.8yrsno datano data
Christof von Kalle
Member of Scientific Advisory Board13.8yrsno datano data
John Agwunobi
Independent Director7.5yrsUS$160.91k0.014%
€ 9.7k
Nick Leschly
Director14.8yrsUS$96.41k0.23%
€ 167.7k
R. Humphries
Member of Scientific Advisory Board13.8yrsno datano data
Elisabeth Leiderman
Independent Director3.1yrsUS$167.91k0.011%
€ 8.2k

13.8yrs

Average Tenure

65yo

Average Age

Experienced Board: BLE0's board of directors are seasoned and experienced ( 13.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 20:57
End of Day Share Price 2024/12/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

bluebird bio, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Zhiqiang ShuBerenberg